Use-result survey of Daichirona for intramuscular injection

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031240151

Enrollment

3000

Registered

2024-06-11

Start date

2024-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of SARS-CoV-2 infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Subjects aged 12 years or older who are receiving Daichirona by intramuscular injection for the first time (2) Subjects who are received Daichirona by intramuscular injection during the contract period (contract period based on the contract with each medical site) (3) Subjects who are received Daichirona by intramuscular injection during the registration period (4) Subjects from whom written informed consent was obtained (1) Subjects aged between 12 years and less than 18 years who are receiving Daichirona by intramuscular injection for the first time (2) Subjects who are received Daichirona by intramuscular injection during the contract period (contract period based on the contract with each medical site) (3) Subjects who are received Daichirona by intramuscular injection during the registration period (4) Subjects from whom written informed consent was obtained

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Safety Specifications of Daichirona (shock, anaphylaxis, myocarditis, pericarditis, Guillain-Barre Syndrome, vaccine associated enhanced disease (VAED) and vaccine associated enhancement of respiratory disease (VAERD), safety when administered to pregnant or breastfeeding women)	—

Contacts

Public ContactGPSP Contact

Daiichi Sankyo Co.,Ltd.

contact_gpsp_jp@daiichisankyo.com+81-3-6225-1059

Outcome results